Photo by diana_pole from unsplash
Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete… Click to show full abstract
Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.
Keywords:
inflammation;
schnitzler;
schnitzler syndrome;
response;
canakinumab leads
Journal Title: Frontiers in Medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Frontiers in Medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!